Feature

Decline in non-Hodgkin lymphoma deaths to continue in 2018


 

Mortality from non-Hodgkin lymphoma is expected to be about 6.1 per 100,000 population in 2018, with the highest rate in Maine and West Virginia and the lowest in Utah.

Approximately 19,910 deaths from non-Hodgkin lymphoma (NHL) are predicted for the year in the United States by the American Cancer Society (ACS) in its Cancer Facts & Figures 2018, based on analysis of 2001-2015 data from the National Center for Health Statistics. That figure is down from the 20,140 predicted for 2017, as the trend in the death rate since 2006 has been a decline of about 2% per year.

Estimated non-Hodgkin lymphoma death rates for 201
The expected number of deaths for 2018, coupled with a current population estimate of nearly 326 million, works out to an expected death rate of 6.1 per 100,000 population. The Census Bureau estimates for the state populations and the deaths projected by the ACS produce expected death rates of 8.2 per 100,000 for Maine and West Virginia and 4.2 for Utah.

Nationally, death rates for NHL were 7.4 per 100,000 for males and 4.5 for females for 2011-2015, and incidence rates were 22.9 per 100,000 for males and 15.8 for females for 2010-2014, the ACS reported.

Over time, the relative survival rate for NHL has gone from 47% in 1975-1977 to 51% in 1987-1989 to 73% in 2007-2013, although there is some disparity between whites, whose respective rates are 47%, 51%, and 74%, and blacks, who have rates of 49%, 46%, and 67%, respectively, the ACS said.

Recommended Reading

AUDIO: Immunotherapy’s role in NHL
MDedge Hematology and Oncology
FDA grants priority review to CAR T-cell therapy for DLBCL
MDedge Hematology and Oncology
Checkpoint inhibitors look safe in rheumatology patients
MDedge Hematology and Oncology
TRANSCEND NHL trial identifies window for CAR T expansion
MDedge Hematology and Oncology
Combo is preferentially active in T-cell lymphomas
MDedge Hematology and Oncology
In situ vaccination eradicates lymphoma, other cancers
MDedge Hematology and Oncology
Combo could treat double-hit lymphoma
MDedge Hematology and Oncology
Risks of MGUS persist beyond 30 years
MDedge Hematology and Oncology
CAR T-cell therapy on fast track in US, EU
MDedge Hematology and Oncology
Generic bortezomib available in US
MDedge Hematology and Oncology